Streetbeat News

Equity Actions

VXRT

Vaxart Inc (NASDAQ:VXRT) stock rose 17.8% to $0.66 following news of a $9.27 million contract from the U.S. Department of Health and Human Services for clinical trial planning. The company also announced the resignation of CEO Andrei Floroiu, with Michael J. Finney stepping in as Interim CEO. Additionally, Vaxart entered into a stock purchase agreement with RA Capital Management for 15.38 million shares at $0.65 each, aiming to raise $10 million for general corporate purposes and to advance its oral vaccine platform. The offering is expected to close around January 18.

Portfolio Pulse from Henry Khederian

January 16, 2024 | 3:59 pm

MA

Mastercard Inc. (NYSE:MA) stock price dropped by 0.26% to $427.99 in the current market session, but has increased by 0.77% over the past month and 16.22% over the past year. The company's P/E ratio of 37.41 is higher than the Financial Services industry average of 36.14, which may suggest that investors expect better future performance or that the stock is overvalued.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 3:45 pm

AXDX

Accelerate Diagnostics Inc (NASDAQ:AXDX) stock reached a new 52-week low after announcing a proposed underwritten public offering of 4.5 million units, causing shares to drop by 23.2% to $2.84. Each unit includes a share of common stock and a warrant, with an option for underwriters to acquire additional shares and warrants. The offering's completion and terms depend on market conditions.

Portfolio Pulse from Henry Khederian

January 16, 2024 | 3:37 pm

AXDX

Accelerate Diagnostics' stock price is trading lower following the announcement of a proposed public offering. The offering is expected to dilute existing shareholders' equity, which typically leads to a decrease in stock price.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 3:36 pm

TSLA

Wedbush analyst Dan Ives commented on Elon Musk's recent statements about wanting increased control over Tesla for AI advancements, maintaining an Outperform rating and a $350 price target on the company. Musk, owning over 12% of Tesla, suggested a dual-class voting structure to achieve around 25% voting control. Ives views AI initiatives as crucial for Tesla and believes that Musk's compensation package delay in court and his share sales for Twitter's acquisition are temporary distractions. Tesla's stock is down 3% but has seen significant growth over the past year and five years.

Portfolio Pulse from Chris Katje

January 16, 2024 | 3:21 pm

GS

During a conference call, the CEO of Goldman Sachs announced the expectation to raise an additional $40 billion to $50 billion in alternatives in 2024. This indicates a significant focus on expanding their alternative investment offerings.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 3:12 pm

GS

Goldman Sachs CEO, during a conference call, expressed confidence in the company's ability to grow its financing activity due to the scale and size of the market. Additionally, the CEO mentioned plans to normalize investment banking activity.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 3:08 pm

DNN

GRDAF

Grounded Lithium Corp. (GLC) has entered into a strategic investment agreement with Denison Mines Corp (Denison), where Denison can earn up to a 75% interest in the Kindersley Lithium Project (KLP) by funding up to CAD$15.15M. The funds will advance the KLP, including a field pilot and other project expenditures. Denison will also become the KLP operator and has purchased a 5% gross overriding royalty on the KLP for CAD$800,000, which may reduce to 2% and be eliminated under certain conditions. The agreement includes three earn-in options, with Denison funding 100% of KLP expenditures during the earn-in period. The deal is subject to TSX Venture Exchange approval and GLC shareholder consent.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 3:05 pm

AXSM

Axsome Therapeutics (NASDAQ:AXSM) has received mixed analyst ratings over the past three months, with 6 analysts offering opinions ranging from bullish to bearish. The average 12-month price target for AXSM is $135.67, with a high estimate of $180.00 and a low of $108.00, indicating a 50.74% increase from the previous average target of $90.00. Analysts from firms including Piper Sandler, HC Wainwright & Co., Cantor Fitzgerald, and Citigroup have provided updates, with one raising the price target from $90.00 to $113.00. Axsome Therapeutics is a clinical-stage biopharmaceutical company focused on CNS disorders. Financially, the company has shown a significant revenue growth rate of 243.07% as of September 30, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -107.62%, ROE of -22.69%, and ROA of -10.26%. Its debt-to-equity ratio of 0.69 is below the industry average.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 3:00 pm

GS

Goldman Sachs CFO has indicated on a conference call that the company plans to stay flexible regarding capital return due to the uncertainty surrounding the proposed Basel III regulations.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 2:53 pm